<DOC>
	<DOCNO>NCT01543477</DOCNO>
	<brief_summary>The purpose study estimate incidence Pure Red Cell Aplasia ( PRCA ) , neutralise antibody , lack efficacy , thromboembolic event treatment Retacrit™ ( epoetin zeta ) administer subcutaneously patient renal anaemia . The key objective study obtain information adverse drug reaction ( ADR ) associate Retacrit™ ( epoetin zeta ) , use epoetin zeta pregnancy lactation data long term use .</brief_summary>
	<brief_title>Post-Authorisation Safety Cohort Observation RetacritTM ( Epoetin Zeta ) Administered Subcutaneously Treatment Renal Anaemia</brief_title>
	<detailed_description>This non-interventional , multi-centre , longitudinal observation define population use prospective cohort design estimate incidence Pure Red Cell Aplasia ( PRCA ) , neutralise antibody , lack efficacy , thromboembolic event treatment Retacrit™ ( epoetin zeta ) administer subcutaneously patient renal anaemia .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<criteria>Patients currently treatment Retacrit™ ( epoetin zeta ) administer subcutaneously renal anaemia . Informed consent give write provide detailed information characteristic observation physician . Patients expect available 3 year observation Any contraindication per current Summary Product Characteristics ( SPC ) Retacrit™</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>